SS18

Synovial Sarcoma Market Pipeline Landscape Report 2022: Comprehensive Insights on 14+ Companies and 14+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 23, 2022
Pharmaceutical, Health, Oncology, Discovery, CTOS, Cancer, SMARCB1, FDA, NDA, Therapy, Synovial sarcoma, BAF, Technology, Gene, Survival, BRD9, AXL, Protein, Clinical trial, Bone sarcoma, IND, Acquisition, News, Ovarian cancer, Mutation, Patient, II, Sarcoma, NSCLC, Toxicity, Annual general meeting, SS18, Large-cell lung carcinoma, Oil, Medical imaging, Pharmaceutical industry, Vaccine

This Synovial-Sarcoma- Pipeline Insight, 2022 report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Synovial-Sarcoma pipeline landscape.

Key Points: 
  • This Synovial-Sarcoma- Pipeline Insight, 2022 report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Synovial-Sarcoma pipeline landscape.
  • Synovial-Sarcoma- Pipeline Insight, 2022 report outlays comprehensive insights of present scenario and growth prospects across the indication.
  • A detailed picture of the Synovial-Sarcoma pipeline landscape is provided which includes the disease overview and Synovial-Sarcoma treatment guidelines.
  • The assessment part of the report embraces, in depth Synovial-Sarcoma commercial assessment and clinical assessment of the pipeline products under development.

Flying Evans delivers another home win for the Toyota Yaris WRC

Retrieved on: 
Monday, October 4, 2021
Rally Japan, WRC, Pressure, Thought, SS18, 2021 Arctic Rally Finland, Darkness, Power Stage, Toyota Yaris, Pain, Rally Finland, Arctic Rally, Smile, Lead, Calendar, Jari-Matti Latvala, TGR, Taxicab, Auction, Amusement arcade, Tourism, Nightclub

The result means that the Toyota Yaris WRC - built in the rally's home city of Jyvaskyla - maintains its unbeaten record on its home roads since its debut in 2017.

Key Points: 
  • The result means that the Toyota Yaris WRC - built in the rally's home city of Jyvaskyla - maintains its unbeaten record on its home roads since its debut in 2017.
  • It's also the 200th WRC podium for Toyota, which becomes only the third manufacturer to reach the figure.
  • With his second win of the season, Evans reduces the gap to championship leader Ogier to 24 points with a maximum of 60 available.
  • I feel we were able to give back to the place where the Yaris WRC was born and to the roads which made it strong.

Foghorn Therapeutics Announces First Patient Dosed in First-in-Human Clinical Trial of FHD-609

Retrieved on: 
Monday, August 23, 2021
SSX, Cancer, Melanoma, BRD9, Iris, Adult, Program, Blood, Gene, Protein, Mum, GLOBE, Pharmacokinetics, ClinicalTrials.gov, Ciliary body, ATPase, Chromatin, Research, Nasdaq, AML, Synovial sarcoma, Therapy, SS18, Cell, Forward-looking statement, MDS, Mutation, BAF, Clinical trial, Safety, Risk, Sarcoma, Choroid, Acute leukemia, Foghorn, Acute myeloid leukemia, Ligament, Microdeletion syndrome, Bone marrow, BRG1, Gene expression, BRM, Vaccine, Pharmaceutical industry, Dietary supplement

CAMBRIDGE, Mass., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today announced that the first patient has been dosed in a first-in-human clinical trial of FHD-609, which is being developed as a treatment for synovial sarcoma. With an initial focus in oncology, Foghorn’s Gene Traffic Control Platform® and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

Key Points: 
  • Foghorn has a broad pipeline of protein degrader programs, and we continue to advance these precision medicines towards clinical development.
  • The open-label, monotherapy, dose-escalation and dose-expansion study will evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of FHD-609 administered intravenously.
  • To learn more about the first-in-human clinical trial of FHD-609 in synovial sarcoma, please visit ClinicalTrials.gov .
  • Foghorn Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system.